Clinical trialPhase 1 / Phase 2Recruiting
Study of ZGGS18 in Patients With Advanced Solid Tumors
A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 15 November 2022
- Expected end
- 1 November 2026
- Enrollment
- 222 participants
- Sites
- 1
- Primary outcomes
- Tolerability of ZGGS18; Safety of ZGGS18
- Sponsor
- Industry
- Results posted
- No
- Last update
- 5 January 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors